Open AccessHyperbaric Oxygen as an Adjunct in Zygomycosis: Randomized Controlled Trial in a Murine Model
Author(s) -
Diana Barratt,
Keith Van Meter,
Philip Asmar,
Terry Nolan,
Chris G. Trahan,
Lisardo García-Covarrubias,
Stephen E. Metzinger
Publication year - 2001
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.45.12.3601-3602.2001
Subject(s) - zygomycosis , rhizopus arrhizus , amphotericin b , deferoxamine , adjunct , medicine , deferasirox , mycosis , hyperbaric oxygen , placebo , anesthesia , randomized controlled trial , surgery , microbiology and biotechnology , antifungal , biology , dermatology , pathology , linguistics , philosophy , biochemistry , alternative medicine , thalassemia , lipase , enzyme
Zygomycosis was induced by injecting CD-1 mice with 5 mg of intraperitoneal deferoxamine and then 10(6) CFU of intravenous and intrasinus Rhizopus arrhizus. The addition of hyperbaric oxygen (2.0 atm absolute twice daily) to amphotericin B did not improve survival over that achieved with amphotericin B and placebo air treatments.